New COVID-19 Treatments Add-On Payment
Published on
Wednesday, August 31, 2022
Did You Know?
In response to the COVID-19 public health emergency (PHE) and as new therapies received approval to treat COVID-19, CMS established the New COVID-19 Treatments Add-on Payment (NCTAP).
Why is Matters?
The NCTAP for eligible COVID-19 products will extend through the end of the fiscal year in which the PHE ends.
On Thursday, August 18, 2022, CMS released a Roadmap for the End of the COVID-19 Public Health Emergency (link).
Based on this information there are key notes and dates to keep in mind related to the ending of the PHE:
- HHS will provide a 60-day notice prior to the renewal date of the COVID-19 PHE if they are not going to extend it.
- The most recent PHE extension was on July 15th and lasts for 90 days (October 13, 2022).
- The 60-day notice has already passed (August 14th) for CMS to provide notice about the end of the PHE.
- The COVID-19 PHE will likely be extended in October for at least one more 90-day period.
- If the PHE is not extended past January 11, 2023, NCTAPs would end September 30, 2023.
What Can You Do?
Visit CMS’ COVID-19 NCTAP specific webpage (link) to identify the therapies that are eligible for the NCTAP.
Article Author: Beth Cobb, RN, BSN, ACM, CCDS
Beth Cobb, RN, BSN, ACM, CCDS, is the Manager of Clinical Analytics at Medical Management Plus, Inc. Beth has over twenty-five years of experience in healthcare including eleven years in Case Management at a large multi-facility health system. In her current position, Beth is a principle writer for MMP’s Wednesday@One weekly e-newsletter, an active member of our HIPAA Compliance Committee, MMP’s Education Department Program Director and co-developer of MMP’s proprietary Compliance Protection Assessment Tool.
